The QualityStocks Daily Monday, March 4th, 2019

Today's Top 3 StockMarketWatch

QualityStocks (RGRX) +174.51%

StocksToBuyNow (ZNGY) +100.00%

MarketClub Analysis (ASND) +74.00%

The QualityStocks Daily Stock List

Thunder Mountain Gold, Inc. (THMG)

Zacks, FeedBlitz, and MarketWatch reported on Thunder Mountain Gold, Inc. (THMG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Established in 1935, Thunder Mountain Gold, Inc. is a junior gold exploration company. It owns interests in numerous U.S. precious metals projects. The Company’s chief asset is The South Mountain Project. The South Mountain Project is on private and patented land in southern Idaho, just north of the Nevada border. Thunder Mountain Gold has its headquarters in Boise, Idaho. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Another main asset of Thunder Mountain Gold is its Trout Creek Project. This is a grass roots gold target in the Eureka-Battle Mountain trend of central Nevada, now under Joint Exploration Agreement with Newmont USA Limited.

Thunder Mountain Gold owns 100 percent of the South Mountain Mine. This mine has a land package comprising about 1,200 acres of mostly private land - both owned outright and leased. A new gold discovery was revealed in 2009 during fieldwork at South Mountain. The Company’s plan of operation for this, subject to business conditions, is to continue to advance the development at the South Mountain Project.

The Trout Creek target is in the Reese River Valley area south of Battle Mountain, Lander County, Nevada. The target consists of 60 unpatented lode mining claims. Trout Creek is on an important trend with Newmont's Phoenix Mine and the Gold Acres, Pipeline. The Cortez Mine sits to the southeast.

Thunder Mountain Gold signed an Amendment, which modifies and extends the exploration Minerals Lease and Agreement with Newmont USA Limited on Thunder Mountain Gold 's Trout Creek Project. The extension permits it more time to complete work requirements on the project and reduces the yearly work obligations.

The Company’s other projects include Clover Mountain. It controls 40 unpatented lode mining claims, covering approximately 800 acres, near Clover Mountain in Owyhee County, Idaho. Also, its West Tonopah Property consists of 8 unpatented lode mining claims totaling 160 acres in the Tonopah Mining District, Esmeralda County, Nevada.

In April of this year, Thunder Mountain Gold announced that it chose SRK Consulting (U.S.), Inc. to complete the Company's South Mountain Preliminary Economic Analysis (PEA). SRK will help develop data gaps. It will also provide guidance on the continuing resource development work planned to start this field season.

The Study will be equally weighted on the development of a new resource model and an optimized mine plan. SRK provides advice and solutions for clients needing specialized services, primarily in the fields of mining, surface and underground geotechnics, water, waste materials, process engineering, the environment and mineral economics.

The South Mountain Project will remain Thunder Mountain Gold’s focus. However, it also continued the exploration and advancement of the Trout Creek Project in 2015.

Thunder Mountain Gold, Inc. (THMG), closed Monday's trading session at $0.09, up 2.27%, on 27,800 volume with 4 trades. The average volume for the last 3 months is 4,986 and the stock's 52-week low/high is $0.035/$0.219.

chart

Bravo Multinational, Inc. (BRVO)

RedChip, InvestorsHub, and MarketWatch reported on Bravo Multinational, Inc. (BRVO), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Bravo Multinational, Inc. is a diversified Company listed on the OTC Markets. Its primary focus is the development and expansion of the Casino Gaming Equipment holdings and business-related activities in Central and South America (specifically Nicaragua, El Salvador, and San Andres, Columbia). The Company previously went by the name Goldland Holdings Co. It changed its corporate name to Bravo Multinational, Inc. in April 2016. Bravo Multinational has its headquarters in Niagara-on-the-Lake, Ontario.

The Company also holds gold/silver mining properties and claims in North America. Its multi-divisional growth strategy is propelled via mergers, acquisitions, and new ventures. At present, Bravo has divisions in Mining Properties and Casino Equipment. Bravo, as it develops, will be adding divisions in International Business Consulting, Wholesale and Manufacturing, and Real Estate Acquisitions.

Concerning Casino Gaming, the Company completed an acquisition transaction on May 6, 2016 with Centro de Entretenimiento y Diversion Mombacho S.A., headquartered in Managua, Nicaragua. On June 1, 2016, Bravo received its first income from this business venture. Additional income payments will be received on the first of each month.

Regarding this transaction, Bravo Multinational will purchase in total 500 slot and video poker gaming machines. All machines have been fully Nationalized and are to be operated under a long-term (year 2033) nationwide national license. Bravo Multinational engaged GameTouch, LLC to coordinate the retail sales segment of Bravo's gaming machines in Nicaragua.

Pertaining to Mining Assets, this involves War Eagle Mines, Silver City, Idaho. Bravo executed a lease agreement with Silver Falcon Mining. This agreement provides for an annual lease payment of $1,000,000 payable in monthly installments of $83,333 per month, and a royalty equal to 15 percent of the proceeds of any ore mined from Bravo property on War Eagle Mountain.

Bravo Multinational is working to expand its business based on five important initiatives. These are the acquisition of existing royalties; providing capital for the exploration, development, and construction of precious metals; monetizing precious metals by-product on existing and future holdings; providing acquisition finance, in partnership with established operating companies, in return for a royalty on the acquired properties; and acquiring mineral properties and leasing the properties to a mining operator receiving rent and royalty payments.

Earlier this month, Bravo Multinational announced that it filed its Q2 ending June 30, 2017, FORM 10-Q with the US SEC. For the three months ended June 30, 2017, Bravo recorded $578,500 in Revenue, and for the six months ending June 30, 2017, the Company recorded $1,251,500 in Revenue. Revenues remain strong over three consistent quarters, as Bravo Multinational’s management works toward profitable quarters, coupled with an increased asset base and decreased liabilities.

Yesterday, Bravo Multinational announced that it completed an asset purchase on August 16, 2017 for 300 slot and video poker machines. This provides an immediate new revenue stream for the Company. The contract is valued at $3,618,000. Bravo anticipates a roughly 30 percent annual return on the assets in Latin America, based on historical income data in similar locations.

Bravo Multinational, Inc. (BRVO), closed Monday's trading session at $0.4837, up 5.02%, on 2,685 volume with 1 trade. The average volume for the last 3 months is 8,663 and the stock's 52-week low/high is $0.021/$0.949.

chart

Citius Pharmaceuticals, Inc. (CTXR)

MicroCapDaily, Stock Commander, Penny Stock Prodigy, DSR News, PHUB News, Damn Good Penny Picks, Penny Picks, OTCtipReporter, PennyStockScholar, Profitable Trader Authority, OTCMagic, Penny Stock Newsletter, and PREPUMP STOCKS reported previously on Citius Pharmaceuticals, Inc. (CTXR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products. The Company’s concentration is on anti-infectives, cancer care, and innovative prescription products utilizing unique, patented, or proprietary formulations of earlier approved active pharmaceutical ingredients. Citius Pharmaceuticals is headquartered in Cranford, New Jersey.

The Company is now advancing two proprietary product candidates: the Mino-Lok™ product and a hydrocortisone-lidocaine formulation. The Mino-Lok™ product is advancing to Phase 3 clinical studies. The Mino-Lok™ product is an antibiotic lock solution. It is used to treat patients with catheter-related bloodstream infections (CRBSIs). Mino-Lok™ is under investigation and not approved for commercial use.

Citius Pharmaceuticals is developing a proprietary topical formulation of hydrocortisone (3%) and lidocaine (5%) to provide anti-inflammatory and anesthetic relief to persons suffering from Grade I and II hemorrhoids. The Company has achieved positive results from a Phase 2a study for hydrocortisone-lidocaine formulation for Grade I and II hemorrhoids.

Citius Pharmaceuticals has commenced the pivotal Phase 3 clinical trial Mino-Lok™. This is the above-mentioned antibiotic lock solution used to salvage infected central venous catheters (CVCs) and to treat catheter related bloodstream infections (CRBSIs). Mino-Lok™ is undergoing development as an adjunctive therapy for the treatment of catheter-related or central line associated bloodstream infection (CRBSI/CLABSI). Mino-Lok™ together with suitable systemic antibiotic(s), is used to preserve central venous access and to avoid the complications and morbidities associated with catheter removal and reinsertion.

The Company has obtained top line data from a survey of 31 physicians clearly showing a need for catheter salvage in patients with indwelling central venous lines, especially when the catheter is a tunneled or an implanted port. Nineteen Infectious Disease experts and 12 Intensivists surveyed all agreed that salvage would be preferable to catheter exchange, fearing that catheter misplacements, blood clots, or vessel punctures can potentially occur during reinsertion. Most were also concerned that viable venous access may not be available. The survey was conducted by a third party in January of this year.

In March 2017, Citius Pharmaceuticals announced that it concluded negotiations to add South America to its global license for Mino-Lok™. South America was the only territory that was not included in the original sub-license between Novel Anti-Infective Technologies, LLC, an affiliate of MD Anderson Cancer Center (MDACC), and Leonard-Meron Biosciences, Inc. (LMB), a wholly-owned subsidiary of Citius Pharmaceuticals.

Citius Pharmaceuticals, Inc. (CTXR), closed Monday's trading session at $1.23, up 1.65%, on 66,125 volume with 164 trades. The average volume for the last 3 months is 148,966 and the stock's 52-week low/high is $0.8582/$3.44.

chart

Provision Holding, Inc. (PVHO)

GrowthPennyStocks, Penny Stock General, Shiznit Stocks, HotStockProfits, PennyDoctor, Stock Beast, RedChip, PennyStockLocks.com, Epic Stock Picks, Equity Observer, Value Penny Stocks, Wolf of Penny Stocks, Small Cap Firm, OTCMagic, MicroCapDaily, and StockRockandRoll reported on Provision Holding, Inc. (PVHO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Provision Holding, Inc., by way of its subsidiary, focuses on the development and distribution of intelligent interactive three-dimensional (3D) holographic display technologies, software, and integrated solutions for consumer and commercial centered application. These are chiefly for advertising and product merchandising markets. The Company’s initial line of display systems has proven to be ideally suited for indoor and outdoor point-of-sale (PoS), merchandising, and PoS related advertising venues. Provision Interactive Technologies, Inc. is a subsidiary of Provision Holding. Provision Holding is based in Chatsworth, California.

Provision’s products include HoloVision displays and 3D Savings Center kiosks. These enable advertisers and customers to reach captive audiences in grocery stores, malls, convenience stores, gas stations, banks, as well as other retail sites. The Company’s proprietary 3D holographic display technologies give advertisers first-rate ability to direct customized content to a target audience.

Provision's 3D holographic display systems represent a unique technology. This technology provides the projection of full color, high-resolution videos into space detached from the screen, without any special glasses. The Company has completed the development and prototype of its latest 3D holographic display system, the HL50.

The HL50 is its largest Holovision™ product. The design of it is for exhibitions and special events. The HL50 uses Provision Interactive Technologies’ patented and award-winning 3D holographic technology. It comes complete. This includes a media player and the Company’s proprietary software, HoloSoft™. The HL50 can project visually stunning 3D holographic videos, detached from the screen, floating in space more than 40 inches outward.

This past June, Provision Interactive Technologies announced that the Company entered into a multi-year partnership agreement with Discount Drug Mart, Inc. This partnership agreement is to install Provision’s proprietary 3D Savings Center kiosks inside Discount Drug Mart stores. The agreement represents the next major retail partnership for Provision.

Prosperity Investments, under its Joyful ATM brand, has entered into an agreement with Provision Interactive Technologies to integrate its 3D holographic display and coupon redemption platform into Joyful ATMs to boost in-store engagement and purchases at point-of-sale (PoS).

Greater than 48,000 Joyful ATM units are planned to undergo deployment across the U.S. and in another 68 countries over the next 72 months, at locations including banks, retailers, convenience stores, gas stations, and government buildings. Via the partnership, the ATMs will project 3D holographic advertising messages to attract customers to the unit. Upon the customer approaching the unit, they can redeem coupons for the advertised products that can be used right away, driving enhanced PoS activity.

Provision Holding, Inc. (PVHO), closed Monday's trading session at $0.018, up 5.88%, on 250,600 volume with 13 trades. The average volume for the last 3 months is 852,792 and the stock's 52-week low/high is $0.0031/$0.039.

chart

Seychelle Environmental Technologies, Inc. (SYEV)

PennyOmega, FeedBlitz, SmallCapVoice, PennyStocks24, and Stock Guru reported on Seychelle Environmental Technologies, Inc. (SYEV), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Seychelle Environmental Technologies, Inc., together with its subsidiaries, designs, assembles, and distributes water filtration systems around the world. The Company provides ionic adsorption micron filters chiefly for portable filter devices, which remove different pollutants and contaminants found in fresh water sources. Seychelle Environmental Technologies is based in San Juan Capistrano, California. Seychelle Water Filtration Products is a DBA of Seychelle Environmental Technologies.

Seychelle markets an extensive line of high-quality portable water filtration products and brands in North America and internationally. Its Ionic Adsorption Micron Filters are the most laboratory and field-tested of their type in the world using Environmental Protection Agency (EPA) protocols and tested to NSF/ANSI Standards 42 and 53 by Broward Testing Laboratory.

The Company’s products include flip-top and pull top bottles, canteens, water pitchers, pure water pumps, stainless steel bottles, in-line filters, pure water bags, pure water pouches, pure water straws, and radiological and PH filters, and also Pump 2 Pure. The Seychelle Pump 2 Pure Kit has Dual Supreme Filtration and one can filter their drinking water using Pump 2 Pure. It is built to reduce up to 99.9999 percent of cysts, bacteria, and viruses from almost any water source.

Seychelle Environmental Technologies offers its Seychelle Regular Filter, Seychelle Standard Filter, Seychelle Advanced Filter, Seychelle Radiological Filter, and Seychelle Extreme-Rad/Adv. Filter. Concerning the Seychelle Water Filtering Technology - Ionic Adsorption Micro Filtration, it is the only personal water filtration system capable of up to 99.99 percent reduction in all four areas of contamination. These four areas are Aesthetic, Microbiological, Chemical, and Dissolved Solids.

Seychelle Environmental Technologies, by way of its DBA Seychelle Water Filtration Products, has appointed the first exclusive sales agent for its New World Filter product in Sri Lanka. The Company said it would begin selling the new and highly profitable product elsewhere worldwide where quality drinking water is not available. The World Filter product requires the exclusive sales agent to source the bottle and cap locally. This is so the finished product will be priced competitively in the market.

In 2017, Seychelle has expanded its sales efforts in Mexico, Sri Lanka, Vietnam, South Korea, Australia, New Zealand, Japan, and China. The Company’s intention is to expand its marketing activities more strongly to the global market as well as E-commerce.

Seychelle is in the process of introducing a number of new products. These include a state-of-the-art drinking water straw for all water conditions and adding to its PH line of products, which includes a bottle and pitcher. Moreover, the Company is completing a hot/cool PH dispenser and await its UL approval.

Seychelle Environmental Technologies, Inc. (SYEV), closed Monday's trading session at $0.098875, up 9.86%, on 2,000 volume with 2 trades. The average volume for the last 3 months is 22,547 and the stock's 52-week low/high is $0.0106/$0.419.

chart

RegeneRx Biopharmaceuticals, Inc. (RGRX)

Stock News Now, TopPennyStockMovers, PennyStockProphet, Penny Pick Finders, Planet Penny Stocks, Buzz Stocks, Stock Onion, and SmarTrend Newsletters reported previously on RegeneRx Biopharmaceuticals, Inc. (RGRX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company. It concentrates on tissue protection, repair, and regeneration with a comprehensive portfolio of product candidates for first-in-class therapeutic peptides. The Company’s mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma, or other pathology. RegeneRx Biopharmaceuticals is based in Rockville, Maryland.

RegeneRx holds numerous issued patents or filed patent applications internationally to enable and protect multiple indications and applications for its product candidates. Currently, the Company has three drug candidates in clinical development for ophthalmic, cardiac, and dermal indications. In addition, it has three active strategic licensing agreements in the United States, China, and Pan Asia (Korea, Japan, and Australia, among others). RegeneRx also has patents and patent applications covering its products in many nations worldwide.

The Company is focusing on moving three distinct Tβ4-based drug candidates through the clinic. These are RGN-137, RGN-259, and RGN-352. RGN-137 is a topical gel formulation of the peptide Tβ4. RegeneRx is developing this as a novel treatment to hasten dermal healing. RGN-137 is a Tβ4-based dermal gel formulation undergoing development for epidermolysis bullosa, which is a rare skin condition.

RegeneRx is also developing RGN-352. RGN-352 is its TB4-based injectable. This is a Phase 2-ready drug candidate designed to be administered systemically to prevent and repair cardiac damage resulting from heart attacks and central nervous system tissue damage associated disorders. These include peripheral neuropathy, multiple sclerosis and traumatic brain injuries - including stroke.

RegeneRx Biopharmaceuticals is centering on the development of Thymosin beta 4 (a novel therapeutic peptide), for tissue and organ protection, repair and regeneration. RGN-259, its TB4-based ophthalmic drug candidate, has been designated an orphan drug for the treatment of neurotrophic keratopathy (NK), which is a main emphasis of the Company's clinical development efforts in the U.S.

This past July, RegeneRx, via its U.S joint venture (JV), ReGenTree LLC, completed patient enrolment and treatment in its second Phase 3 clinical trial in around approximately 600 patients with dry eye syndrome. Additionally, the Company is at the same conducting a 46-patient Phase 3 clinical trial in patients with NK, targeted for completion in 2018. Also, RGN-259 is undergoing development in patients with dry eye syndrome in Asia by way of RegeneRx's two Asian partnerships.

At the end of August, RegeneRx Biopharmaceuticals announced it completed a license expansion agreement with GtreeBNT for the rights to RGN-137, RegeneRx's topical gel formulation of thymosin beta 4 (Tβ4), in Europe, South Korea, Japan, Canada, and Australia.

Earlier this month, RegeneRx announced that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for Thymosin beta 4 (Tβ4) for use in the treatment of dry eye syndrome. Tβ4 is the active pharmaceutical ingredient in RegeneRx's proprietary drug candidate, RGN-259. This is a first-in-class product candidate designed for topical administration to patients suffering from dry eye syndrome.

RegeneRx Biopharmaceuticals, Inc. (RGRX), closed Monday's trading session at $0.35, up 174.51%, on 65,760 volume with 16 trades. The average volume for the last 3 months is 61,094 and the stock's 52-week low/high is $0.07/$0.30.

chart

Pharma-Bio Serv, Inc. (PBSV)

Zacks reported previously on Pharma-Bio Serv, Inc. (PBSV), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Pharma-Bio Serv, Inc. is a compliance, project management, and technology transfer support consulting firm. The Company’s primary business is Food and Drug Administration (FDA) and other international regulatory compliance agency related services, with integrated portfolio services including microbiological and chemical testing services. This includes microbiological and chemical testing services for clients in the Pharmaceutical, Biotechnology, and Chemical, Medical Device, Cosmetic, Food and Allied Products industries, at its laboratory testing facility in Puerto Rico. Pharma-Bio Serv is based in Dorado, Puerto Rico. The Company also has operations in the U.S., Ireland, and Spain.

Pharma-Bio Serv supports its clients by way of the product lifecycle. This includes research and development (R&D) Studies; NDA Documentation and Filings; PAI Readiness; Audit & Inspection Preparation, Management and Response, and Post Approval. Furthermore, this includes Quality Systems; Technology Transfer; Validation, and Manufacturing Controls & Process Support.

The Company’s worldwide team includes top engineering and life science professionals, quality assurance managers, as well as directors. Also, the Company’s services include "Pharma Serv Academy." This division provides technical and regulatory standards seminars/training conducted by industry experts.

Pharma-Bio Serv’s divisions include Scienza Labs, the abovementioned PharmaServ Academy, and Metrologix. Scienza Labs provides microbiological and analytical testing, field support, method development, and validation. Metrologix provides laboratory and on-site calibration services, calibration program management, risk management, compliance remediation, and instrument rental.

This past September, Pharma-Bio Serv announced Net Revenues for the three and nine months ended July 31, 2017 were $4.0 and $11.9 million, respectively. This represents a decrease of roughly $0.9 and $2.9 million, or 18.2 percent and 19.8 percent, respectively, versus the same periods the year prior.

The decrease for the three months ended July 31, 2017, versus the same period last year, is primarily because of a decline in projects in the Puerto Rico consulting market of $0.9 million. The Company’s other divisions sustained minor revenue gains/losses or remained constant, versus the same period the year prior.

Mr. Victor Sanchez, Pharma-Bio Serv’s Chief Executive Officer, said, "Our strategic re-alignment and investment is ongoing and our goals are to achieve long-term profitability on our non-performing operations. To that end Europe is a focus for our attention, we have also refocused our US consulting services strategy with a more streamlined business development approach, which has resulted in operational expense savings during the second and third quarters of the current fiscal year…”

Pharma-Bio Serv, Inc. (PBSV), closed Monday's trading session at $1.10, up 2.80%, on 3,400 volume with 3 trades. The average volume for the last 3 months is 4,444 and the stock's 52-week low/high is $0.432/$1.25.

chart

Exicure, Inc. (XCUR)

Penny Stock Hub, TradingView, AdisInsight, InvestorsHangout, Insider Monkey, BioPortfolio, Street Insider, MarketWatch, Business Wire, Stockopedia, 4-Traders, Stockwatch, Simply Wall St, OTC Markets, WalletInvestor, OpenInsider, InsiderMole, and Interactive Brokers reported on Exicure, Inc. (XCUR), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Exicure, Inc. is a clinical stage biotechnology company based in Chicago, Illinois. The Company is developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's lead programs center on oncology, inflammatory diseases, and genetic disorders. The Company lists on the OTC Markets’ OTCQB.

Exicure's intellectual property (IP) portfolio includes more than 140 pending patent applications and more than 55 allowed or issued patents. These filings cover a range of inventions, including fundamental nanoparticle manufacturing breakthroughs and numerous application-specific improvements.

Concerning Partnering and Licensing, Exicure's strategy is to maximize the potential of its Spherical Nucleic Acid (SNA) technology platform through in-house development, collaborations, as well as licensing. Furthermore, it may establish platform partnerships with pharmaceutical companies across manifold indications or within specific therapeutic areas.

Exicure's proprietary 3-dimensional, Spherical Nucleic Acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide assortment of cells and tissues. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics. This is the safe and effective delivery into cells and tissues.

SNA constructs exhibit first-rate transfection efficiency into many cell and tissue types, including the skin, without carriers or transfection agents. Additionally, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.

Exicure is utilizing its SNA technology to mobilize the body's natural defense against cancer. The Company’s lead immunotherapy compound, AST-008 (initially being investigated in selected solid and hematological tumors) is a toll-like receptor 9 agonist. The design of it is to use the SNA's beneficial properties to drive a potent anti-cancer immune response.

Exicure has started topical dosing in its Phase 1 clinical trial for XCUR17 in patients with mild to moderate psoriasis. XCUR17 is an antisense SNA. It targets the mRNA encoding IL-17RA, a protein considered essential in the initiation and maintenance of psoriasis.

The Company has also completed the third cohort of volunteers in its AST-008 trial. It announced the planned enrollment of a Phase 1b/2 trial expected to begin in late 2018 in combination with checkpoint inhibitors.

Exicure, Inc. (XCUR), closed Monday's trading session at $2.81, up 0.36%, on 45,951 volume with 12 trades. The average volume for the last 3 months is 27,013 and the stock's 52-week low/high is $2.66/$6.50.

chart

Marathon Gold Corporation (MGDPF)

Stockhouse, 4-Traders, TipRanks, MarketWatch, TradingView, The Street, Resource World, WalletInvestor, StockInvest, Stockwatch, YCharts, Streetwise Reports, Barchart, Penny Stock Hub, Mining.com, Capital Equity Review, OTC Markets, Marketbeat, and Investors Hangout reported on Marathon Gold Corporation (MGDPF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

A gold exploration Company, Marathon Gold Corporation is quickly advancing its 100 percent owned Valentine Lake Gold Camp in Newfoundland. Currently, the Valentine Lake Gold Camp hosts four near-surface, mainly pit-shell constrained deposits with measured and indicated resources totaling 2,137,400 oz. of gold at 1.99 g/t and inferred resources totaling 1,104,700 oz. of gold at 1.99 g/t. Most of the resources occur in the Marathon and Leprechaun deposits, which also have resources below the pit shell.  Both deposits are open to depth and on strike. Marathon Gold is headquartered in Toronto, Ontario. The Company lists on the OTC Markets Group’s OTCQX.

The Valentine Lake Gold Camp is accessible by year-round road. It is in close proximity to Newfoundland’s electrical grid. Recent metallurgical tests have demonstrated 93 percent to 98 percent recoveries via conventional milling and 50 percent to 70 percent recoveries via low cost heap leaching at the Leprechaun and Marathon Deposits.

Drilling in 2018 continues to center on expanding the Marathon Deposit at surface and to depth and also exploration drilling along the boggy covered area between the Marathon and Sprite Deposits. Gold mineralization has been traced down over 350 meters vertically at Leprechaun and close to a kilometer at Marathon.

The four deposits outlined so far occur over a 20-kilometer system of gold bearing veins. Much of the 24,000-hectare property has had little detailed exploration activity so far. Marathon’s exploration projects include Baie Verte (100 percent owned - Newfoundland) and the Bonanza Mine (100 percent owned – Oregon).

This past May, Marathon Gold completed its initial PEA (Preliminary Economic Assessment) on the Valentine Lake project. This is the first economic study undertaken at Valentine Lake.

The Company stated that the results of the study were very encouraging and positive, confirming a potential mining operation involving heap leaching and conventional processing, producing 188,500 ounces of gold annually for the first 10 years of its life at an all-in sustaining cost (AISC) of US$595 per ounce and generating a pre-tax IRR (Internal Rate of Return) of 34 percent and an after-tax IRR of 25 percent on estimated pre-production costs of US$380 million.  The expectation is that the project will produce an after-tax NPV (Net Present Value- 5 percent) of US$367 million (CAD$466 million) for an 11-year mine life. The after-tax payback period is 2.8 years.

In late July, Marathon Gold announced the intersection of high-grade gold mineralization at depth within the main corridor of the Marathon Deposit. MA-18-295 was very successful in intersecting a broad interval of high grade gold in en-echelon stacked QTP veining, which returned 7.97 g/t Au over 59.0 meters including 57.74 g/t Au over 5.0 meters, 48.12 g/t Au over 2.0 meters, and 27.81 g/t Au over 1.0 meter. This drill hole was part of the current continuing infill drilling program at the Marathon Deposit designed to upgrade inferred material into the measured and indicated category.

Marathon Gold Corporation (MGDPF), closed Monday's trading session at $0.78, up 3.27%, on 45,700 volume with 12 trades. The average volume for the last 3 months is 45,733 and the stock's 52-week low/high is $0.49/$0.95.

chart

Freedom Leaf, Inc. (FRLF)

MicroSmallCap, Promotion Stock Secrets, Daily Marijuana Observer, OTC Markets, Stockhouse, InvestorsHub, CFN Media Group, SmallCapVoice, Penny Stock Tweets, and StocksToBuyNow reported on Freedom Leaf, Inc. (FRLF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Freedom Leaf, Inc. (The Marijuana Legalization Company™) is a group of international, vertically integrated hemp businesses and cannabis media companies. It is a leading go-to resource in the cannabis, medical marijuana, and industrial hemp industry. Freedom Leaf is building a diverse portfolio of valuable businesses through strategic mergers, acquisitions, and acceleration projects across the industry. Freedom Leaf has its corporate office in Las Vegas, Nevada. Leafceuticals, Inc. is a wholly-owned division of Freedom Leaf.

Freedom Leaf does not handle, grow, sell, or disperse marijuana. The Company targets acquisitions of high growth and niche companies. Its strategy is to identify select technology companies and companies that are involved in cannabis and industrial hemp genetics, intellectual property (IP), bioscience, nutraceutical, and pharmaceutical product development.

Its flagship publication is Freedom Leaf Magazine, The Good News in Marijuana Reform. Freedom Leaf produces a portfolio of news, print, and digital multi-media verticals, websites, and web advertising, for the ever-developing and changing cannabis, medical marijuana, and industrial hemp industry.

Freedom Leaf has its LaMarihuana.com. This is the Spanish Speaking community's top cannabis website. Freedom Leaf also has its www.Marihuana-Medicinal.com. This is the largest Medical Cannabis information portal in Spanish.

Hempology® is the Company’s exclusively branded product line. Hempology® is now vertically integrated from seed to consumer, processing CBD and a whole spectrum of whole-hemp extracts for the entourage-effect. Freedom Leaf also has its hemp-based rolling paper company, Plants to Paper.

Freedom Leaf has acquired 100 percent of Green Market Europe S.L. (GME). GME is a Spanish producer of hemp products. Freedom Leaf announced this past April that it consummated its previously announced acquisition of the Irie CBD Product Line. This includes virtually all assets, trademarks, formulating equipment, formulas and products. Irie is a California-based CBD, "Cannabidiol", product line.

At the beginning of August, Freedom Leaf announced that it consummated a 100 percent acquisition of Tierra Science Global, LLC. Tierra specializes in health supplements supporting peak bio-energy levels in humans. These are presently distributed by way of direct sales teams and well established affiliate programs in the U.S., Europe and Asia.

Freedom Leaf, Inc. (FRLF), closed Monday's trading session at $0.225, up 0.85%, on 331,674 volume with 67 trades. The average volume for the last 3 months is 533,370 and the stock's 52-week low/high is $0.09/$0.795.

chart

Envision Solar International, Inc. (EVSI)

OTCJournal, FeedBlitz, Hotstocked, Greenbackers, RedChip, SmarTrend Newsletters, Stock News Now, SmallCapVoice, and Stockwire reported on Envision Solar International, Inc. (EVSI), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Envision Solar International, Inc. is the leading renewably energized EV charging, outdoor media, and energy security products enterprise. The Company is a developer of solar products and proprietary technology solutions. It designs, manufactures, and deploys unique, renewably energized, EV charging and media and branding systems. OTCQB-listed, Envision Solar International is based in San Diego, California.

The Company’s products include the patented EV ARC™ and Solar Tree® product lines. All of Envision Solar’s products can be enhanced with EnvisionTrak™ patented solar tracking, ARC Technology™ energy storage, SunCharge™ Electric Vehicle Charging Stations, and digital advertising packages.

Envision Solar has designed and incorporated EnvisionTrak, its proprietary and patented tracking solution, to the Solar Tree structure. It has deployed its latest generation of Solar Tree products, the Solar Tree HVLC (High Value, Low Cost) collection.

The new Solar Tree product incorporates its latest engineering and fabrication improvements. The Company’s Solar Tree® structure works as a billboard for a company’s green credentials. This is while producing clean energy and improving the aesthetics of any parking lot.

In addition, Envision Solar has developed the above-mentioned EV ARC™. The Company has observed that the EV ARC™ (Electric Vehicle Autonomous Renewable Charger) can solve numerous problems associated with electric vehicle charging infrastructure deployments. The EV ARC™ fits inside a parking space. It generates enough clean, solar electricity to power up to 225 miles of EV driving in a day.

In Q2 2018, Envision Solar International realized Revenue of $844,495. This represents a 66 percent increase over the same period last year and the highest Q2 Revenue in the Company’s history. Q2 Gross Profits increased by 243 percent over the same period last year.

Envision realized FH (First Half) Revenues of $3.7M. This represents a 324 percent increase over 2017 and higher than any full year in the Company’s history. FH gross profits increased 413 percent over the same period the year prior. Revenue was attained via new and repeat customer orders of Envision’s EV ARC™ products from government and enterprise customers.

Yesterday, Envision Solar International announced the appointment of Mr. Bob Schweitzer as an independent member of its Board of Directors. Mr. Schweitzer has served as a Director and executive in business and financial organizations for the past 44 years. He is presently the Chairman of the Board at PetMeds (PETS) where he additionally serves as Compensation Committee Chair and on the Audit, Nominating and Investment Committees.

Envision Solar International, Inc. (EVSI), closed Monday's trading session at $0.205, up 2.50%, on 7,360 volume with 10 trades. The average volume for the last 3 months is 34,742 and the stock's 52-week low/high is $0.145/$0.429.

chart

Alternate Health Corp. (AHGIF)

InvestorsHub, The Street, Daily Marijuana Observer, WalletInvestor, Weed Newswire, MicroCapFinder, OTC Insider, MarketWatch, GuruFocus, CannabisFN, OTC Markets, and Marijuana Index reported on Alternate Health Corp. (AHGIF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Alternate Health Corp. is a global medical cannabis company listed on the OTCQB. It provides software solutions for the medical cannabis industry. The Company employs best in class technology, research, education, production, and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. Alternate Health is based in San Antonio, Texas.

The Company is a diversified healthcare investment and Holdings Company. It operates via a network of subsidiaries that share proprietary, highly secure cloud-based software solutions to boost efficiencies and protect patient data.

Its companies are: Alternate Health Clinics; Alternate Health Labs; Alternate Medical Media; Alternate RX; CanaPass; and VIP-Patient. Alternate Health has operations in Venice, California; San Antonio, Texas; and Toronto, Ontario.

Alternate Health announced on May 10, 2018, that its Management received Board of Directors approval to explore a spinoff plan for the Company's non-cannabis assets. The estimation is that this will take a minimum of three to four months to complete the due diligence process.

The Company develops software applications and processing systems for the medical industry utilizing proprietary technology platforms (VIP-Patient & CanaPass systems) to assist doctors in their practice management and patients with their need for first-rate medical care. Alternate Health’s services include practice management and controlled substance management software, blood analysis and toxicology labs, clinical research, continuing education programs, nutraceutical products, and security and control services to the emerging medical cannabis industry.

Alternate Health announced this past April the transformation of the CanaPass Patient Management system to a complete Ethereum-based blockchain Electronic Medical Records (EMR)/Electronic Health Records (HER) system.
Moreover, the Company announced at the beginning of May a proposed plan that it believes will substantially increase shareholder value via a spinoff of its blockchain payment systems, Alternate Health Labs subsidiary, and other non-cannabis assets, into a new corporation that will apply to be listed on a major U.S. exchange.

Alternate Health has taken a leadership position in blockchain financial and healthcare solutions. A key product is its Zi App Blockchain Payment Gateway. It was designed originally to enable digital payments in cannabis. However, the system has earned considerable interest as a payment solution for even larger markets, including multi-level marketing, commercial leases, as well as equipment rentals.

Earlier this month, Alternate Health announced that it signed a binding contract on August 6, 2018, to provide laboratory services for a large multistate laboratory provider. The Company expected to start testing samples this month. It is targeting a ramp up to a monthly sample rate of 25,000 - 30,000 by December 2018.

Alternate Health Corp. (AHGIF), closed Monday's trading session at $0.3248, up 1.15%, on 5,460 volume with 8 trades. The average volume for the last 3 months is 17,244 and the stock's 52-week low/high is $0.2175/$1.85.

chart

Sayona Mining Limited (DMNXF)

OilandGas 360, The Street, Barchart, Your Drilling News, CentralCharts, OTC Markets, Penny Stock Hub, WalletInvestor, HotCopper, Metals News, Investors Hangout, Penny Stock Tweets, 4-Traders, Stockwatch, MarketWatch, Stockhouse, Capital Equity Review, InvestorsHub, and Predict Wall Street reported on Sayona Mining Limited (DMNXF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Sayona Mining Limited, together with its subsidiaries, engages in the identification, acquisition, evaluation, and exploration of mineral assets in Australia and globally. The Company chiefly explores for lithium and graphite. It formerly went by the name DiamonEx Limited. It changed its corporate name to Sayona Mining Limited in May 2013. Listed on the OTC Markets, Sayona Mining is based in Paddington, Australia.

Sayona Mining’s focus is on sourcing and developing the raw materials required to make lithium-ion batteries. The Company’s primary emphasis is the development of the advanced stage Authier Lithium Project in Quebec. The Authier Project is 45 kilometers northwest of the city of Val d’Or, a major mining service center in Quebec. Authier mineralization is hosted in a spodumene-bearing pegmatite intrusion with more than 18,000 meters of drilling in 139 holes.

The Authier Lithium Project has advanced, near term development potential. It has a Pre-Feasibility Study (PFS) demonstrating technical and economic viability. The Project area comprises 19 mineral claims totaling 653 hectares. It extends 3.4 kilometers in an east-west, and 3.1 kilometers in a north-south direction, respectively. The location of the Mineral claims is over Crown Land. Sayona Mining completed greater than 8,000 meters of drilling during 2016 and 2017.

The Authier Lithium Project is amenable to simple open-cut mining and processing methods. The project is in close proximity to development infrastructure. In July 2016, Sayona acquired 100 percent of the Authier project for CAD$4 million. In addition, the Company controls a portfolio of lithium and graphite exploration projects in Western Australia.

Concerning Western Australia, Sayona Mining has 17 tenements in the Pilbara Region, covering a total area of 1918km2. Of these, nine were acquired by way of a deal with Great Sandy, with the Mallina Project – E47/2983, being the flagship project.

The East Kimberley Graphite Project is Sayona’s strategic entry into the graphite market. In 2015, the Company announced a strategic entry into the large flake graphite market through securing a large ground position in the East Kimberley area of Western Australia. The Kimberley region is a proven province for high purity, large flake graphite.

The East Kimberley project is 240 kilometers south of Wyndham Port and 220 kilometers south-south-west of the regional center, Kununurra. The Project includes one granted tenement and three separate tenement applications. The Project covers 278 km2. It comprises two areas, Keller and Corkwood. Sayona Mining has 100 percent of the graphite interests across four tenements in the East Kimberley, following the completion of two option-to-purchase agreements.

This past June, Sayona Mining reported the start of a testing program to produce lithium carbonate and lithium hydroxide from the Authier pilot plant lithium concentrate. The Company recently completed a pilot plant program that processed five tons of Authier drill core into greater than 400 kilograms of spodumene concentrate.

This program demonstrated that a 6 percent Li2O concentrate could be produced at a metallurgical recovery of 79 percent. SGS Canada, Inc. will perform the downstream testing program.

Sayona Mining Limited (DMNXF), closed Monday's trading session at $0.0196, up 3.16%, on 17,906 volume with 3 trades. The average volume for the last 3 months is 84,523 and the stock's 52-week low/high is $0.012/$0.054.

chart

Stem Holdings, Inc. (STMH)

Market Screener, Jet Life Penny Stocks, Dividend Investor, InvestorsHub, OTC Markets, Wallet Investor, MarketWatch, Barchart, 4-Traders, Stockhouse, Simply Wall St, last10k, Morningstar, TradingView, YCharts, Midas Letter, Stockopedia, InvestorsHangout, and GuruFocus reported on Stem Holdings, Inc. (STMH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Stem Holdings, Inc. develops strategic brands for contemporary cannabis consumers. The Company builds and partners with companies in numerous sectors of the marijuana market from distribution to hemp cultivation. Stem buys, improves, and leases properties for use in the cannabis production, distribution, and sales industry in Oregon. OTCQB-listed the Company is headquartered in Boca Raton, Florida.

Stem brands and partnerships consist of Incredibles; Reefer Distribution Co.; Supernatural; Cannavore, and PUL. The Company’s brands and partnerships also include TJ’s Gardens; GreenTFarms; Travis x James; Dose-Ology; G Pen, and Craft Extracts.

Regarding Stem Retail Properties, the Company builds boutique retail stores. TJ’s Provisions is its flagship marijuana dispensary, situated in Eugene, Oregon, ten minutes from the downtown. Stem also has its TJ’s on Willamette marijuana dispensary approximately one mile from the University of Oregon campus.

In addition, the Company has its TJ's on Powell. This is a 2,000 square foot retail storefront in Portland, Oregon. TJ’s on Powell has a prime south-facing position on a busy highway route.

Regarding Stem’s Cultivation & Processing Properties, the Company has its 42nd Street facility. This large warehouse serves as a first-class indoor cultivation facility just outside of Eugene, Oregon. This property has 22 grow rooms.

The Company also has its Mulino Farm greenhouse cultivation facility. The property in Clackamas County has 12 commercial-grade greenhouses. Additionally, Stem has its Applegate Farms cultivation facility. It consists of 40 acres in Jacksonville, Oregon. Output at Scale is 2,000 lbs annually.

Moreover, the Company has its TJ’s Wallis. This Eugene property will include two facilities. They will provide space for cultivation and processing. This location has a premier commercial kitchen for edibles production and grow rooms and an extraction lab.

Furthermore, Stem’s TJ’s Las Vegas property outside of Vegas will allow cultivation, processing, and distribution operations for the fast-growing Nevada cannabis market. This property is 5,450 square feet.

Stem Holdings, Inc. (STMH), closed Monday's trading session at $1.73, up 1.76%, on 15,586 volume with 24 trades. The average volume for the last 3 months is 10,445 and the stock's 52-week low/high is $1.319/$7.75.

chart

The QualityStocks Company Corner

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX)

The QualityStocks Daily Newsletter would like to spotlight Foresight Autonomous Holdings Ltd. (FRSX).

Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX), an innovator in automotive vision systems, announced today an additional sale of a prototype of its flagship product QuadSight™, a four-camera vision system targeted for the semi-autonomous and autonomous vehicle market. The prototype system was ordered by one of Israel’s leading defense companies. Revenue from the prototype system sale is expected to total tens of thousands of dollars.

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX), founded in 2015 and headquartered in Israel, is a technological innovator in automotive vision systems and driver assistance technology. Through its wholly owned subsidiary, Foresight Automotive Ltd., Foresight is engaged in the design, development and commercialization of stereo/quad-camera vision systems and V2X cellular-based solutions for the automotive industry based on 3D video analysis, advanced algorithms for image processing and sensor fusion. The company’s powerful and patented stereoscopic technology is derived from field-proven technology that has been deployed throughout the world for almost two decades.

Foresight’s innovative autonomous driving solutions are based on mature, proprietary stereoscopic image technology that uses two synchronized cameras to mimic human depth perception and produce a three-dimensional image. This 3D image can anticipate possible collisions with other vehicles, cyclists, pedestrians and other obstacles. The technology provides highly accurate real-time alerts about the vehicle’s surroundings while in motion. The systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts.

The company’s patents provide IP protection for its robust and proven proprietary stereoscopic technology, which was developed using the security technology of Foresight’s major shareholder, Magna B.S.P.

Foresight has developed three main products:

  • QuadSight™. This breakthrough detection system sets the bar for autonomous vehicle vision. It features nearly 100 percent obstacle detection with almost zero false alerts and operates optimally under all weather and lighting conditions, including darkness, rain, fog, haze and glare. QuadSight™ is the first quad-camera multi-spectral vision solution of its kind, driven by advanced and proven image processing algorithms. The system consists of two sets of stereoscopic infra-red and visible-light cameras that enable highly accurate and reliable obstacle detection for seamless 24/7 vision.
  • Eyes-On™. This solution uses advanced algorithms for accurate depth analysis and obstacle detection to provide a unique stereo vision Advanced Driver Assistance System (ADAS). It can detect all potential obstacles regardless of shape, form or material, including other vehicles, cyclists, pedestrians and animals. It has an accuracy and reliability of almost 100 percent and near zero false alerts.
  • Eye-Net™. This is a cellular-based accident prevention solution that is designed to provide real-time pre-collision alerts to vehicles and pedestrians. This proprietary system is deployed on smartphones and cloud-based servers operating on existing cellular networks, and it eliminates the need for additional designated hardware. Eye-Net™ is designed to provide a complementary layer of protection to advanced driver assistance systems and extends this protection to road users who are not in direct line of sight. It is optimally designed for both urban environments and high-speed scenarios to provide protection for the most vulnerable road users. On March 28, 2018, Foresight announced that it had completed a successful feasibility study of its Eye-Net™ accident prevention solution involving 120 users of Android and iOS cell phones located across Israel.

In 2017, Foresight sought more opportunities within the international market. The Company signed pilot agreements with three leading car manufacturers in China and completed pilot projects meeting all pre-defined requirements and criteria. In addition, FRSX completed a pilot project with Uniti Sweden.

Studies by the Insurance Institute for Highway Safety continue to emphasize the dramatic reduction in accidents and injury-related crashes reported when vehicles are equipped with collision avoidance systems. A recent study by the Institute states that the rate of single-vehicle, sideswipe and head-on crashes was 11 percent lower in vehicles with the warning systems. More importantly, the study shows collision avoidance technology cut the rates of injury crashes of the same type by 21 percent.

Foresight Autonomous Holdings, Inc. also holds a 32 percent interest in RailVision, a company that develops advanced systems for railway safety and maintenance. RailVision has successfully completed 13 tests in Israel, Germany, Italy and Switzerland in addition to a real-time system test with a European railway operator. Over the course of 2017, RailVision successfully completed rounds of financing totaling $5.8 million and started the process of licensing the system according to European standards.

Haim Siboni is the founder of Foresight and has served as the company’s chief executive officer and director since 2015. Siboni, a passionate entrepreneur, has an extensive background in the marketing and business management sectors in the fields of electronics, video, TV, multimedia, computerized systems, line and wireless telecommunication, design and development of systems and devices, including electro-optic radar systems. He is the founder and CEO of Magna B.S.P., Foresight’s major shareholder and a leading innovator in the field of homeland security surveillance solutions.

Foresight Autonomous Holdings Ltd. (FRSX), closed the day's trading session at $1.87, up 5.34%, on 51,412 volume with 169 trades. The average volume for the last 3 months is 37,225 and the stock's 52-week low/high is $1.47/$4.45.

Recent News

chart

Millennial Lithium Corp. (TSX.V: ML) (FSE: A3N2) (OTC: MLNLF)

The QualityStocks Daily Newsletter would like to spotlight Millennial Lithium Corp. (OTC: MLNLF).

Millennial Lithium Corp. (TSX.V: ML) (FSE: A3N2) (OTC: MLNLF) is pleased to announce the inauguration of its on-site permanent Project Center, including a 60-100 person camp, an on site laboratory, and a process pilot plant under construction which is to be commissioned in the second quarter. In line with the Company's commitment to sustainability, the Project Center is to be powered by a state-of-the-art hybrid solar power system that will reduce CO2 output and costs for fuel.

Millennial Lithium Corp. (TSX.V: ML) (FSE: A3N2) (OTC: MLNLF) is engaged in the development of the Pastos Grandes lithium project in Salta Province, Argentina. The company’s Pastos Grandes project totals approximately 10,000 hectares located in geopolitically stable, mining-friendly jurisdictions. The company also enjoys a solid strategic partnership with GCL, a Chinese solar giant that has become Millennial Lithium’s lead investor with approximately $30 million investment to date.

Millennial Lithium’s compelling valuation places it with a $123 million market cap, third only to Lithium Americas and Orocobre in the region. The company holds a strong cash position of C$40 million and is pursuing a strategic plan moving forward in 2019 that includes an updated NI 43-101 resource report and a full bankable feasibility study, including supporting evaporation ponds and pilot processing plant.

Projects

Argentina currently produces 17 percent of the world’s lithium supply. Lithium is at the cornerstone of a quiet industrial revolution as it brings together energy, automotive and technologies companies to foster a lasting move away from carbon-based resources. Lithium demand is expected to grow at an annual rate of 22 percent through 2025 with increased demands for lithium-ion batteries used in electric vehicles and battery-based energy storage leading the way.

Millennial Lithium has a world-class lithium brine asset strategically located in the heart of the Argentinean portion of the South American “Lithium Triangle.”

The company’s flagship lithium brine project, Pastos Grandes, is following a two-year timeline to production as a result of some of the best infrastructure in the Lithium Triangle. Located 231 km from the city of Salta at an elevation of 3,800 meters, Pastos Grandes is accessible year-round with all-weather access to paved highways, power and natural gas. Based on proven technology, brine extraction, solar evaporation and conventional lithium brine processing, Millennial Lithium’s preliminary economic assessment (PEA) of the Pastos Grandes project, completed by international engineering firm WorleyParsons, estimates a mine life of 25 years with a three-year ramp up to 25,000 tonnes per year of Lithium-Carbonate. A 3 tonne-per-month lithium carbonate pilot plant is currently being built for use at the site.

To date, 23 exploration wells are completed with $40 million spent in development. A revised Resource Estimate is planned for Q1 2019. Four pumping wells are also to be completed in Q1 2019 with two water wells currently being drilled in support of the ongoing Feasibility Study, also being completed by WorleyParsons. Infrastructure buildup is underway, including completion of a 40-man camp, hybrid solar-diesel power system, pilot plant and laboratory with ICP unit for rapid sample assays and a liming plant for treating concentrated brines form the pilot ponds. Millennial Lithium is also constructing a Pastos Grandes community center/warehouse and all-purpose building that is central to building community relations with local residents.

Encouraging results from an extended pumping test of a second production-scale well at the Pastos Grandes project revealed that at a pumping rate of 15 liters/second (L/s), the lithium content remained consistent over the 23-day trial period with a drawdown of approximately 57 meters with rapid recovery. Estimated transmissivity (the rate at which the brine moves through the aquifer) is 40 square meters per day, demonstrating the aquifer’s strong potential to sustain a long-term pumping rate of 15 L/s.

Brine sampling completed daily during the pumping test over the 23-day period revealed the chemistry is consistent with lithium ranging from 482 mg/L and 518 mg/L, averaging 495 mg/L. The best lithium values occurred during the last five days of the pumping test. The magnesium to lithium (Mg/Li) ratio averages 5.3 and the average potassium to lithium ratio (K/Li) is 10.5 and the average sulphate to lithium ratio (SO4/Li) is 16.4. Sampling was conducted in accordance with CIM guidelines for brine resource evaluation, with an appropriate chain of custody and QA/QC program in place for ensuring veracity, accuracy and precision of the analytical results.

Management Team

Millennial Lithium’s highly prospective lithium assets and strategies are bolstered by a world class management and board with extensive experience in lithium and large development projects.

President/CEO/Director Farhad Abasov, MBA, has founded and managed a number of mining aassets with successful exits in the last few years. He was president and CEO of Allana Potash which was sold to Israel Chemicals Ltd. for $170 million in 2015. As executive chairman of Rodinia Lithium, Abasov developed lithium bring projects in Argentina in 2016. He was also co-founder of Potash One, acquired by German potash company K+S for $430 million in 2010, and was senior vice president, strategy, at Energy Metals, acquired by Uranium One for $1.88 million in 2007.

Iain Scarr, BSc., MBA, is Chief Operating Officer with a wealth of experience in lithium brine development and operations. He worked at Rio Tinto, industrial minerals, including lithium resource development in Serbia. Scarr led feasibility work at Sal de Vida lithium brine project (Galaxy Resources, Argentina); completed the Rincon lithium brine project feasibility study (Enirgi, Argentina); and is a resident of Salta with established, strong relationships in the region.

Chief Financial Officer Max Missiouk, CPA, CMA, has served as a CFP and controller for a number of publicly listed resource and venture companies including Allana Potash Corp. and Crocodile Gold Corp. He is a CPA (CMA) and has a post-graduate degree in banking and finance management.

Peter J. MacLean, Ph.D., P.Geo, is senior vice president, technical services. He has more than 30 years of exploration and development experience in North America, South America and Africa. Most recently, MacLean acted as senior vice president/exploration of Allana Potash Corp. and directed all exploration and development activities on its flagship Danakhil Potash Project in Ethiopia including managing the company’s Feasibility Study and overseeing pilot solution mining and evaporation pond trials. He has also worked extensively on projects throughout the Americas and is fluent in Spanish.

Peter Ehren, M.Sc., AusIMM CP, process consultant, has been involved in lithium brines for more than 20 years. Ehren has worked at the Salar de Atacama as part of SQM’s team of leading evaporation technology experts, rising to the position of R&D manager. He has worked in the majority of lithium basins worldwide for numerous projects including Orocobre’s Salar de Olaroz Project.

Millennial Lithium Corp. (OTC: MLNLF), closed the day's trading session at $1.3161, up 1.98%, on 10,031 volume with 17 trades. The average volume for the last 3 months is 15,388 and the stock's 52-week low/high is $0.67/$2.79.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences, Inc. (OTCQB: PBIO), a leader in the development and sale of pressure-based instruments and platform technologies to the life sciences and other industries worldwide, today announced a collaboration with The Steinbeis Centre for Biopolymer Analysis & Biomedical Mass Spectrometry ("The Steinbeis Centre"), a world-renown German research organization.

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed the day's trading session at $3.85, up 2.67%, on 6,188 volume with 17 trades. The average volume for the last 3 months is 14,640 and the stock's 52-week low/high is $1.52/$4.94.

Recent News

chart

Sharing Services, Inc. (SHRV)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services, Inc. (SHRV).

Sharing Services Inc. (OTCQB: SHRV), a diversified holdings company focused on reshaping the way modern entrepreneurs succeed, offers over 25 years of leadership in the direct selling industry. The company employs a dynamic business model which focuses on mentorship of subsidiary companies. Sharing Services specializes in offering management, buying power, merchant processing, manufacturing and administrative services, enabling mentee companies to develop and expand.

Sharing Services, Inc. (SHRV), headquartered in Plano, Texas, is a diversified holdings company focused on reshaping how entrepreneurs succeed today. Sharing Services Inc. owns, operates or controls an interest in a variety of companies specializing in the direct selling industry that either sell products to the consumer directly through independent representatives or offer services that range from health and wellness, energy, technology, insurance services, training, media and travel benefits. SHRV has created the “Blue Ocean Strategy,” which melds three keys together to implement the company’s vision. These keys include elevating home-based entrepreneurs, known as “Elepreneurs,” utilizing the direct selling channel to generate 100 percent organic growth.

Sharing Services Inc. subsidiaries include:

  • A growing international network of home-based entrepreneurs, called “Elepreneurs”
  • Growing selection of health and wellness products dedicated to elevating the well-being of all people
  • Insurance from auto, home and life to health benefit discounts and health insurance that help families elevate their options
  • Wholesale travel and payment programs with travel concierges that empower more families to go on vacation
  • Live seminars and training events – from Vacationars™ to EduTainment – that elevate the skills and knowledge of entrepreneurs around the world
  • Unique compensation and reward programs crafted to help entrepreneurs elevate their health, wealth and happiness

Sharing Services recently expanded its corporate footprint by moving to a 10,000 square foot facility in Plano, Texas, that offers room to expand as the company grows and its subsidiaries flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

“The opportunity to expand to the rest of this new building over the course of the next six to 12 months ensures we won’t have to move again anytime soon,” Sharing Services Inc. Chairman Robert Oblon said. “We are on track for very significant growth here in the U.S., as well as upcoming international expansion, so this move is in preparation for what’s in front of us.”

The company recently signed a joint venture agreement with Health Wealth & Happiness Limited (“HWH”) to expand its “Elepreneurs” brand and market its products throughout Asia. The newly formed company will be named “Elepreneurs Asia Limited” and will have marketing and sales rights to China, Hong Kong, Macau, South Korea, Japan, Taiwan, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam and Papua, New Guinea. A soft launch of the Elepreneur program is scheduled sometime later in 2018 with HWH CEP Fai Chan and his team leading the effort. Formed in Hong Kong, Health Wealth & Happiness Limited is dedicated to working with visionary partners like Sharing Services Inc. to deliver the best products and services to improve the well-being of consumers.

Nearly 1,000 people attended Sharing Services, Inc.’s first “Elepreneur Happiness Convention,” held March 2-3, 2018, in Dallas, Texas. Attendees arrived from several countries including the U.S., Canada, Mexico, Singapore and Hong Kong. Keynote speakers included several internationally known motivational leaders –  Shawn Achor, Sandra Yancey, John Fleming and Les Brown – who provided exceptional material and inspirational discussion points.

“The enthusiasm of our attendees and the early success that we are experiencing is incredible considering our growth has been 100 percent organic, with almost no marketing from the company,” Oblon said. “I’m speechless by the dedication of our Elepreneur leaders and their entire teams, as they share our incredible line of products that have helped so many people.”

Sharing Services and its management team plan to travel the U.S. to hold several mini conferences to expand on the messages presented at its Happiness Convention that focus on helping people become “healthier, happier and wealthier.” Details of the company’s aggressive global expansion initiatives are soon to be announced, Oblon said.

The law firm of Gardere Wynne Sewell LLP has been retained as outside corporate counsel for all general business matters. The Dallas-based law firm will represent Sharing Services, Inc., and its subsidiaries as the company utilizes the direct selling channel for a significant component of its overall growth strategy.

John “JT” Thatchwas appointed president and chief executive officer of Sharing Services, Inc., at a March 1, 2018, annual shareholder meeting. Thatch has successfully started, owned and operated several sized businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist Sharing Services Inc. as the company aims to expand and increase revenues.

Sharing Services, Inc. (SHRV), closed the day's trading session at $0.235, even for the day. The average volume for the last 3 months is 42,208 and the stock's 52-week low/high is $0.17/$0.59.

Recent News

chart

TransCanna Holdings Inc. (CSE: TCAN)

The QualityStocks Daily Newsletter would like to spotlight TransCanna Holdings Inc. (CSE: TCAN).

TransCanna Holdings Inc. (CSE: TCAN) (XETR: TH8) (FSE: TH8) ("TransCanna" or the "Company") is pleased to announce that it has appointed Arni Johannson as President. Mr. Johannson has over thirty years operating and investing in both private & publicly traded companies throughout Canada and the USA. Mr. Johannson's has had numerous successful exits across a number of different sectors and has served on more than 20 corporate board of directors during this time.

TransCanna Holdings Inc. (CSE: TCAN) through its subsidiaries specializes in assisting clients who are cannabis farmers and manufacturers get recognized by end consumers who in turn purchase their products. TransCanna offers or will be offering services to support almost every aspect of the cannabis-related eco-system; from branding and design, to transportation and distribution, to marketing and sales.

California’s legalized adult-use recreational marijuana market opened for business January 1, 2018. The state’s Bureau of Cannabis Control is responsible for regulating all commercial activities in the state including cultivation, distribution and transportation. Moving cannabis products in the California marketplace is extremely challenging due to municipal and state laws and regulations, which can differ among cities and counties. Since cannabis remains illegal under federal law, Department of Transportation regulated companies are barred from participating in the market, which means companies looking to excel in the sector must hold a state-issued distributor license from the Bureau of Cannabis Control.

TransCanna has already entered into an Intellectual Property Rights and Royalty Agreement for the Track & Trace software platform required by the state of California. TCM Distribution, the operating company managed by TransCanna, has received a transportation and distribution permit from the city of Adelanto and a temporary transportation and distribution permit from the state of California. TransCanna has also executed a land lease to build a 10,000-square-foot transportation and distribution facility in Adelanto.

TransCanna is strategically creating a distribution network throughout California that places its facilities no further than a three-hour drive from most any client. The company is in the process of leasing or purchasing properly licensed and permitted warehouses strategically located throughout California along with new secure trucks, sprinter vans and/or armored vehicles.

TransCanna plans to create its own portfolio of branded products for the cannabis and hemp sectors. The company’s management team intends to translate the skills, knowledge and experience gained from a combined 60 years of branding and marketing experience in the music, professional sports and alcohol industries into TransCanna and the cannabis industry.

As part of the “TransCanna Way,” the company intends to manage most aspects of the supply chain from upper end procurement, branding, transportation and distribution, to marketing and sales.

Leading TransCanna as its CEO and chairman is James Pakulis, who has three decades of experience working with public and private entrepreneurial companies in a variety of emerging and high-growth sectors. He is formerly the president and a director of Lifestyle Delivery Systems Inc. (CSE: LDS) (OTCQB: LDSYF), a vertically integrated cannabis-related entity operating in California. Pakulis was chairman and CEO of General Cannabis Inc. which from 2010 to 2012 owned WeedMaps. Pakulis oversaw the company’s growth from zero to over $16 million in annual revenue in less than 24 months.

The company’s strategic advisors include individuals with extensive experience in branding, marketing, sales, distribution, production and supply chain management.

For additional information, call: (604) 609-6199

TransCanna Holdings Inc. (CSE: TCAN), closed the day's trading session at $2.63, off by 0.75%, on 45,469 volume with 51 trades. The stock's 52-week low/high is $0.77/$2.90.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Nicotine LLC, a subsidiary of Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), recently secured research and development (“R&D”) funding in exchange for equity and licensing rights. Utilizing its DehydraTECH absorption platform, Lexaria will execute a wide-ranging series of clinical studies on oral forms of nicotine delivery. To view the full article, visit: http://nnw.fm/P89i4.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $1.30, off by 3.70%, on 125,085 volume with 137 trades. The average volume for the last 3 months is 184,074 and the stock's 52-week low/high is $0.75/$2.43.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech Inc. (OTCQB: ETST), a biotech company focused on the nutraceutical and pharmaceutical fields, is looking to expand its cannabidiol (“CBD”) product distribution in wider markets in the United States. The company has reached agreements with CannaBiz and Desert Sun Distribution to sell its CBD product line to chiropractors, dispensaries, pharmacies, health care practitioners, athletic clubs and clinics throughout the country (http://nnw.fm/76CTl). Also today, the company was featured today in the 420 with CNW by CannabisNewsWire.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.672, off by 4.00%, on 24,041 volume with 28 trades. The average volume for the last 3 months is 34,491 and the stock's 52-week low/high is $0.421/$2.45.

Recent News

chart

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

ChineseInvestors.com Inc. (OTCQB: CIIX), a premier provider of financial news and education for the Chinese-speaking community, this morning announced the appointment of Patrick Leung as its new chief financial officer, effective March 1, 2019. To view the full press release, visit: http://nnw.fm/v12XD.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed the day's trading session at $0.465, off by 2.11%, on 38,089 volume with 39 trades. The average volume for the last 3 months is 92,691 and the stock's 52-week low/high is $0.365/$1.25.

Recent News

chart

Choom Holdings Inc. (CSE: CHOO) (OTC: CHOOF)

The QualityStocks Daily Newsletter would like to spotlight Choom Holdings Inc. (CHOOF).

Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) was featured today in the 420 with CNW by CannabisNewsWire.

Choom Holdings Inc. (OTC: CHOOF) (CSE: CHOO) channels the laid-back spirit of Hawaii to the Okanagan region of British Columbia with a generous nod to the inspirational, yet unofficial, history of the 1970s “Choom Gang,” a group of buddies in Honolulu (including former President Barack Obama) who knew how to relax with “choom,” the local’s term for marijuana. Choom’s trademark slogans pivot off another unconventional phrase (“Say Hello to…”), bringing a heady dose of good times and good friends together as the company invites investors to “Say Hello to Choom™” as it lights up the adult recreational cannabis market in Canada.

Choom™ has been an ACMPR (Access to Cannabis for Medical Purposes Regulations) applicant since November 2013 in Vernon, B.C. The company’s first application has received security clearance and is now in the detailed review stage. They also recently announced their second late-stage ACMPR application, which is in its confirmation of readiness stage. Cannabis Compliance Inc. has been retained to help expedite Choom’s initial license applications to ensure the company’s readiness for legalization of recreational marijuana in Canada mid-summer 2018.

True to the company’s character, Choom™ is retrofitting two large facilities – No. 1 in Vernon, B.C., and No. 2 on Vancouver Island – to house its cannabis growing facilities. Phase 1 of the Vernon property will provide Choom™ with 6,800 square feet of growing space, capable of producing 660 kg/year of cannabis at an estimated revenue of $6.6 million, excluding oils. The company expects this facility to be completed by July 2018, the same month that Canada is expected to formally legalize recreational marijuana for adult use. A potential Phase 2, to be completed by the end of 2018, would add another 6,800 square feet for a total of 1,500 kg/year capacity, which would nearly double No. 1’s revenue. A Level 9 vault is also planned with a storage capacity of 15,000 kg. While the No. 2 facility on Vancouver Island is smaller – 4,500 square feet – its retrofit is also slated to be completed by July 2018. Plans include doubling this space as well, which would add about $9 million in annual revenue, excluding cannabis oils.

Choom™ announced its retail dispensary strategy with the intention of establishing market leadership in reaching the Canadian cannabis consumer. The partner program is already in the retail space design stage as the company seeks to build a chain of branded retail cannabis dispensaries in jurisdictions in Canada where recreational cannabis is legal. Choom™ Stores will have a cool, modern layout and design created to emit an authentic “Aloha” vibe. Choom™ is all about producing high-grade cultivars and curating them for a bigger audience.

A savvy, experienced management team includes Chris Bogart, president and CEO; John Oh, R.P.I.C., Operations Manager; Robert Bayrack, Master Grower, S.P.I.C.; and Adrian Robinson, Strategic Advisor. Bogart has over two decades of international experience in capital markets and was a co-founder of InMed Pharmaceuticals and Magnum Uranium. He has structured complex equity financing transactions in the U.S., Europe and Canada. Bogart is joined on the Board of Directors by Kevin Pull, Stephen Tong and John Oh.

While the medical marijuana industry is expected to double by 2021 to 500,000 registered users, the true highlight of the recreational cannabis represents the key cultural shift set to launch in Canada. With an estimated $4.9B to $8.7B retail market coming, now is the right time for a Recreation Brand like Choom™ to be involved in this growing industry. Establishing and maintaining Choom™ premium brand loyalty is a key factor in the company’s growth strategy. Get ready to “Say Hello” to opportunity, good times and good friends with Choom™.

Choom Holdings Inc. (CHOOF), closed the day's trading session at $0.36, off by 1.93%, on 325,313 volume with 151 trades. The average volume for the last 3 months is 334,876 and the stock's 52-week low/high is $0.285/$1.13.

Recent News

chart

First Cobalt Corp. (TSX.V: FCC) (OTC: FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF).

First Cobalt Corp. (TSX-V: FCC; ASX: FCC; OTCQX: FTSSF) (the "Company") is pleased to report that a 611-metre drill hole has extended mineralization by an additional 150 metres downdip in the central portion of the Iron Creek Cobalt Project in Idaho, USA.

First Cobalt Corp. (TSX.V: FCC) (OTC: FTSSF), with headquarters in Canada, is the largest land owner in the Cobalt Camp in Ontario with control of over 10,000 hectares (nearly 25,000 acres) of prospective land and 50 historic cobalt/silver mines. The company’s assets include a mill and the only permitted cobalt extraction refinery in North America capable of producing battery material, providing an integrated solution for cobalt projects. First Cobalt began drilling in the historic Cobalt Camp in 2017 and seeks to build shareholder value through new discovery and growth opportunities.

First Cobalt’s 2018 $C7 million drilling program, which includes testing different styles of mineralized areas throughout the Cobalt Camp in more than 10 past-producing mines known to contain cobalt, is a significant expansion over its 2017 exploration activities. The company received positive test drill results from the Bellellen mine location, with early results confirming the presence of high-grade cobalt and nickel, prompting First Cobalt to increase its drilling program at that site. A prospecting sampling program of existing muckpiles around the camp’s historic mines, trenches, pits and surrounding bedrock could provide an early production scenario.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world’s current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

First Cobalt is embracing innovation in the mining sector, utilizing a digital compilation of 100-plus years of mining and geological data spanning the historically prolific Cobalt Mining Camp’s lifespan. First Cobalt’s management team is also assessing the ability of artificial intelligence to accelerate the discovery cycle. As a member of the Mineral Exploration Research Centre (MERC) and Metal Earth Project, First Cobalt conducts regional geophysical surveys for geological interpretation of structures controlling cobalt-silver mineralization.

The company’s clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance.

First Cobalt Corp. (FTSSF), closed the day's trading session at $0.14615, off by 2.12%, on 70,287 volume with 24 trades. The average volume for the last 3 months is 167,864 and the stock's 52-week low/high is $0.108/$0.906.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

Continued interest in energy systems that are friendly to the planet’s environment is creating new opportunity for exponential growth at SinglePoint Inc. (OTCQB: SING), a diversified holding company specializing in M&A activity that promotes new technologies. On February 26, SinglePoint announced that it has signed an agreement to acquire Direct Solar and AI Live Transfers – two companies utilizing the Lending Tree Model to market products and services to solar power consumers (http://nnw.fm/6u7Ci). Also today, the company was highlighted in an article examining how a building interest in and support of renewable energy sources such as solar energy, savvy companies are identifying ways to establish a firm foothold in the sector.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed the day's trading session at $0.0187, off by 3.11%, on 4,420,300 volume with 221 trades. The average volume for the last 3 months is 6,237,592 and the stock's 52-week low/high is $0.0106/$0.0709.

Recent News

chart

BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT)

The QualityStocks Daily Newsletter would like to spotlight BriaCell Therapeutics Corp. (BCTXF).

An equity investment of C$500,000 into BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) by the company’s recently-appointed director, Jamieson Bondarenko (http://nnw.fm/jSjK6), underscores the vital importance of BriaCell’s proprietary drug development efforts to millions of cancer patients.

BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT), based in Berkeley, CA, and headquartered in Vancouver, British Columbia, is a clinical-stage biotechnology company focused on the development of targeted immunotherapy for advanced breast cancer.

BriaCell hopes to develop and market the first off-the-shelf personalized immunotherapy for the treatment of advanced breast cancer.

The results of two previous proof-of-concept clinical trials produced encouraging results in patients with advanced breast cancer. Most notably, one patient with breast cancer that had spread to other sites (metastatic cancer) responded to Bria-IMT™ with a substantial tumor shrinkage in multiple sites including the breast, the lung, soft tissues and even the brain. Similar observations have been confirmed more recently in additional patients, and BriaCell is developing BriaDX™ as a way to identify those patients most likely to respond.

BriaCell has recently completed recruitment of a Phase I/II study (NCT03066947) of Bria-IMT™, the Company’s lead product candidate, in advanced breast cancer patients showing an outstanding safety profile and excellent efficacy. BriaCell is currently enrolling advanced breast cancer patients in a combination therapy trial (NCT03328026) of Bria-IMT™ with Keytruda® (Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.) or Yervoy® (Yervoy® is a registered trademark of Bristol-Myers Squibb Company). For further information on the Phase IIa clinical trials, please visit trial NCT03066947 and trial NCT03328026.

BriaCell’s pipeline also includes Bria-OTS™, the first off-the-shelf personalized immunotherapy for advanced breast cancer; and, a companion diagnostic product BriaDX™. By using BriaDX™ to identify and treat the patients who would most likely benefit from their immunotherapies, BriaCell expects to personalize the treatment for the patients, and bring hope to thousands of cancer patients who currently have few-to-no treatment options.

Breast Cancer Statistics

The National Cancer Institute estimates that more than 265,000 new cases of female breast cancer will be diagnosed in the U.S. during 2018, and that more than 40,000 women in the U.S. will die from the disease. Approximately 12 percent of women will be diagnosed with breast cancer at some point during their lifetime, based on 2013-2015 data.

Using its novel technology platform and strong R&D capabilities, BriaCell believes it has the opportunity to address this market, as well as have the opportunity to develop immunotherapy candidates for other cancer indications.

The global cancer immunotherapy market is expected to reach nearly USD$203 billion by 2025.

BriaCell Therapeutics Corp. (BCTXF), closed the day's trading session at $0.07335, off by 3.51%, on 10,000 volume with 2 trades. The average volume for the last 3 months is 20,293 and the stock's 52-week low/high is $0.049/$0.135.

Recent News

chart

Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE)

The QualityStocks Daily Newsletter would like to spotlight Pacific Rim Cobalt Corp. (OTCQB: PCRCF).

Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) is a Canada-based exploration company focused on the acquisition and development of production-grade cobalt deposits, a key raw material input for the growing lithium-ion battery industry.

Pacific Rim Cobalt and its Cyclops Nickel-Cobalt Project, located in the Depapre District, Jayapura Regency, Papua Province, Republic of Indonesia, is uniquely positioned in a region with potentially the largest source of cobalt outside of Africa. Strategically located near China, the world’s largest cobalt buyer, the Cyclops Project is a laterite (iron-hosted) mineral prospect, rich in cobalt and nickel. Cobalt consumption in China is on-track to use over 8,000 tonnes of cobalt annually by 2021 for electric vehicle production alone and is projected to remain the world’s largest cobalt consumer for many years to come.

Global demand for renewable power is fueling a massive shift from traditional energy supply chain economics to cobalt-reliant lithium-ion batteries, the world’s most widely used power source for portable applications such as electric vehicles and other high-tech applications.

Pacific Rim Cobalt management has concluded that strategic access to major markets offers the most important factor to servicing the rising demand for cobalt. The company’s acquisition of its initial asset in Indonesia offers near surface, strong nickel-cobalt mineralization in an area with excellent infrastructure including a nearby workforce, supplies, sealed roads, ocean access, nearby port facility and gentle topography. The project area, nestled on the north coast of Papua, Indonesia, establishes Pacific Rim Cobalt well within the economically attractive ocean-going transportation range to Asia and its lucrative, growing industrial markets.

Exploration efforts are currently focused on establishing a maiden compliant resource for the Cyclops project, both in historically identified and drill-tested prospects as well as previously unexplored areas of the claims. During the first nine months of 2018, the company focused on assembling the necessary agreements to access northern areas of the project hosting historically identified mineralized zones. Mapping, sampling and a mini-bulk sample within the mineralized zones has been completed, along with a small-scale program in the previously unexplored far southern area of the project. With surface access to priority targets now established, Pacific Rim Cobalt will initiate drilling and extract additional mini-bulk samples for further metallurgical testing.

“We are excited and optimistic about the unique possibility of developing this project into an asset that will add shareholder value and position the company to play a future role in the battery metals supply chain,” Pacific Rim Cobalt CEO Ranjeet Sundher recently stated (http://nnw.fm/u1HNs). “We expect the near-surface nature of cobalt/nickel mineralization at the Cyclops project will lend itself well to low-cost, logistically straightforward drilling. We thus anticipate the opportunity to undertake a resource calculation study, as well as ongoing metallurgy and process option testing, will present itself in the near future. It’s going to be a busy year ahead, and we look forward to getting the drills turning and building value.”

Pacific Rim Cobalt’s world-class management team includes Sundher, who has over 20 years of capital markets experience. Sundher is also president of Canrim Ventures Ltd., a Singaporean advisory firm specializing in early stage project finance and structure. He previously founded Indogold Exploration, a Jakarta-based mining service firm, and has raised over $40 million for companies in which he was a founder/partner.

Chief Financial Officer Steve Vanry has 25 years of professional experience in senior management positions with public and private natural resources companies, providing expertise in capital markets corporate finance, mergers and acquisitions, regulatory compliance, accounting and financial reporting.

Andre Talaska serves as country manager and technical supervisor. He has over 30 years of experience in the mining and exploration industry and has held senior positions with several companies in Australia and southeast Asia. Shakir Juffry, business development/engineering, is a chemical engineer and extractive metallurgist by background training who has over 20 years of experience in the Indonesian mining and minerals exploration field. Toto Suarto Sajali, operation and development manager, is a mining engineer with over 15 years of experience in Indonesian project assessment, development and operations.

Pacific Rim Cobalt Corp. (OTCQB: PCRCF), closed the day's trading session at $0.13359, up 0.83%, on 14,250 volume with 8 trades. The average volume for the last 3 months is 24,198 and the stock's 52-week low/high is $0.0701/$0.5925.

Recent News

chart

Kontrol Energy Corp. (CSE: KNR) (OTC: KNRLF) (FSE: 1K8)

The QualityStocks Daily Newsletter would like to spotlight Kontrol Energy Corp. (CSE: KNR).

Kontrol Energy Corp. (CSE: KNR) (OTC: KNRLF) (FSE: 1K8) specializes in the integration of smart energy technologies and solutions for North American commercial and industrial property owners and operators to help them benefit from energy cost savings and minimize greenhouse gas emissions. Kontrol is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology and is ranked by Canadian Business and Maclean’s as the 7th fastest growing startup in 2018.

Kontrol’s leadership position is reshaping the way customers use, manage and strategically allocate energy resources to realize immediate energy savings by gaining more control over energy consumption and demand in real-time.

As the fastest growing global “fuel source,” energy efficiency is big business with industry analysts noting this multi-trillion-dollar market offers significant opportunities over the next five years. Established market segments include: energy retrofits ($71.4 billion); distributed generation ($179.9 billion); energy analytics ($33.5 billion); and greenhouse gas/carbon measurement, reduction ($1.2 trillion). Each $1 invested in energy efficiency displaces up to $3 of utility-scale transmission and distribution investment, according to the International Energy Agency.

Formed in 2015 by a group of energy veterans who recognized that the energy efficiency industry is one of the fastest growing fuel sources for the global economy, Kontrol is committed to enhancing and improving its customers sustainability objectives. In less than two years, Kontrol has grown its revenue run rate to $16 million from $1.8 million, delivering on stated goals and objectives as it seeks to continue this pattern through accretive acquisitions and the expansion of the company’s smart energy technologies.

Up to 50 percent of Kontrol’s overall revenues are recurring annually, and the company’s 2019 outlook includes strategic initiatives that will expand the company’s smart energy technologies to U.S. markets, bring additional accretive and strategic acquisitions, and accelerate recurring SaaS revenues.

Kontrol’s strategy of disciplined mergers and acquisitions includes the following highlights:

  • Acquisition of Log-One Ltd.’s award-winning energy conservation technology, Energy Management System (“EMS”), an intelligent, occupancy-based heating and air-conditioning control system for commercial and multi-residential real estate. Rebranded as Kontrol EMS Technology, the company has added IoT and mobile application capabilities, creating a recurring revenue platform through a Software-as-a-Service (SaaS) platform.
  • Acquisition of ORTECH Consulting Inc., an engineering consulting firm specializing in Greenhouse Gas (GHG) reporting, emission testing, air quality testing and renewable energy/power consulting.
  • Acquisition of Efficiency Engineering Inc. (“EE Inc.”), which provides engineering services to industrial, municipal and commercial building owners across Canada. EE Inc. provides detailed energy efficiency analysis, energy audits, management of facility system solutions, electrical and mechanical design and energy conservation studies.
  • Acquisition of MCW Dimax Ltd. (“MCX”), a firm specializing in solutions for the application of energy software to analyze the management of complex heating, ventilation and cooling systems for large residential, commercial, and mission critical real estate owners.
  • Acquisition of CEM Specialties Inc. (“CEMSI”), a market leader in turn-key emission monitoring, equipment and solutions.

The company has also established entry into the North American cannabis market as a supplier of integrated energy efficiency solutions and technologies. Within this market, Kontrol is focused on assisting cannabis growers to reduce the cost of energy and support mission critical infrastructures. To date, Kontrol has secured two contracts to provide energy efficiency services with Licensed Producers in the Canadian cannabis sector.

The Kontrol Energy group of companies is currently saving its customers more than 40 million kilowatt hours of electricity per annum and providing a corresponding reduction in GHG emissions.

Kontrol’s management team includes CEO Paul Ghezzi, a leader in clean tech, renewable energy development, solar project financing and distributed generation. Ghezzi has global experience in power generation projects under Feed-in Tariff programs and Power Purchase Agreement programs for both commercial and utility-scale projects. COO Kristian Lavereau has more than 25 years of experience in the IT solutions (analytics and mobile computing), energy optimization and efficiency (intelligent control systems, solar PV, lighting). Claudio Del Vasto, CPA, CA | CFO, is a senior finance executive with an extensive background in corporate finance, strategy and business development.

Kontrol Energy Corp. (CSE: KNR), closed the day's trading session at $0.61, up 3.39%, on 11,690 volume with 8 trades. The average volume for the last 3 months is 12,932 and the stock's 52-week low/high is $0.46/$1.05.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.